
Amryt Pharma plc AMYT
Annual report 2021
added 12-23-2023
Amryt Pharma plc Operating Expenses 2011-2026 | AMYT
Annual Operating Expenses Amryt Pharma plc
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 109 M | 52.2 M | 27.9 M | 25.9 M | 6.95 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 109 M | 6.95 M | 44.4 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M | ||
|
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | ||
|
BioNTech SE
BNTX
|
512 M | $ 95.5 | -3.88 % | $ 27.2 B | ||
|
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | ||
|
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | ||
|
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | ||
|
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | ||
|
Cerus Corporation
CERS
|
149 M | $ 2.59 | -4.78 % | $ 494 M | ||
|
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | ||
|
Athira Pharma
ATHA
|
18.7 M | - | - | $ 269 M | ||
|
Cardiff Oncology
CRDF
|
49.6 M | $ 1.61 | -2.42 % | $ 108 M | ||
|
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | ||
|
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | ||
|
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B | ||
|
Atreca
BCEL
|
98.7 M | - | -11.76 % | $ 5.79 M | ||
|
Berkeley Lights
BLI
|
152 M | - | -7.31 % | $ 87 M | ||
|
Cue Biopharma
CUE
|
54 M | $ 34.94 | 17.05 % | $ 3.31 B | ||
|
Calithera Biosciences
CALA
|
125 M | - | -10.95 % | $ 876 K | ||
|
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | ||
|
CymaBay Therapeutics
CBAY
|
133 M | - | - | $ 3.45 B | ||
|
ChemoCentryx
CCXI
|
120 M | - | - | $ 3.74 B | ||
|
Editas Medicine
EDIT
|
201 M | $ 3.04 | 1.33 % | $ 270 M | ||
|
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - | ||
|
Caladrius Biosciences
CLBS
|
23.4 M | - | -16.75 % | $ 25.8 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
61.5 M | - | - | $ 231 M | ||
|
Exelixis
EXEL
|
598 M | $ 44.42 | 0.57 % | $ 12.1 B | ||
|
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
708 M | $ 22.35 | 0.72 % | $ 3.7 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | ||
|
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
226 M | - | - | $ 2.18 B | ||
|
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | ||
|
Dynavax Technologies Corporation
DVAX
|
137 M | - | - | $ 2.02 B | ||
|
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | ||
|
Galapagos NV
GLPG
|
709 M | $ 28.39 | -0.13 % | $ 2.69 B | ||
|
Grifols, S.A.
GRFS
|
1.64 B | $ 8.27 | 0.49 % | $ 6.83 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 3.5 | 5.42 % | $ 5.76 M | ||
|
Eiger BioPharmaceuticals
EIGR
|
62.1 M | - | -9.21 % | $ 2.55 M | ||
|
Eloxx Pharmaceuticals
ELOX
|
34.4 M | - | -5.68 % | $ 8.28 M | ||
|
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | ||
|
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | ||
|
ImmuCell Corporation
ICCC
|
9.8 M | $ 8.87 | 1.66 % | $ 80.1 M | ||
|
InflaRx N.V.
IFRX
|
52.4 M | $ 1.97 | -7.51 % | $ 152 M | ||
|
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M | ||
|
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M |